Akathisia: an updated review focusing on second-generation antipsychotics - PubMed
- ️Thu Jan 01 2009
Review
. 2009 Apr 21;70(5):627-43.
doi: 10.4088/JCP.08r04210.
Affiliations
- PMID: 19389331
- DOI: 10.4088/JCP.08r04210
Review
Akathisia: an updated review focusing on second-generation antipsychotics
John M Kane et al. J Clin Psychiatry. 2009.
Abstract
Objective: To provide a brief description of the pathophysiology of akathisia, the challenges of diagnosing and treating this condition, and potential associated clinical issues. Also, to provide a review of the literature on the incidence of drug-induced akathisia associated with the use of second-generation antipsychotics (SGAs) and first-generation antipsychotics (FGAs).
Data sources: English-language literature with no date restrictions cited in PubMed was searched for the keywords akathisia, placebo, neuroleptic, or haloperidol, and the generic names of SGAs (clozapine, risperidone, olanzapine, quetiapine, ziprasidone, or aripiprazole).
Study selection: Limits were set to search clinical trials, meta-analyses, or randomized controlled trials reviewing data from adult schizophrenia or bipolar disorder clinical trials. Studies including SGA comparisons with placebo and with FGAs, and also between SGAs themselves, were selected. Studies that specifically assessed akathisia (either subjectively or objectively or both) were included. Studies reporting generalized results pertaining to extrapyramidal symptoms (EPS) were excluded.
Data extraction: The incidence of akathisia, EPS rating scores, and required medications for the management of movement disorders were reviewed.
Data synthesis: Seventy-seven trials were included in the comparative review. Akathisia was observed with the use of all the SGAs. The akathisia incidence reported in bipolar disorder trials was generally higher compared with schizophrenia trials. The incidence reported for FGAs was consistently higher than that reported for SGAs, regardless of the patient population studied.
Conclusion: Akathisia remains a concern with the use of SGAs. More accurate and standardized evaluations are required for a better understanding of the nature and incidence of akathisia.
Copyright 2009 Physicians Postgraduate Press, Inc.
Similar articles
-
Fraguas D, Correll CU, Merchán-Naranjo J, Rapado-Castro M, Parellada M, Moreno C, Arango C. Fraguas D, et al. Eur Neuropsychopharmacol. 2011 Aug;21(8):621-45. doi: 10.1016/j.euroneuro.2010.07.002. Epub 2010 Aug 10. Eur Neuropsychopharmacol. 2011. PMID: 20702068 Review.
-
Moteshafi H, Stip E. Moteshafi H, et al. Expert Opin Drug Saf. 2012 Sep;11(5):713-32. doi: 10.1517/14740338.2012.712682. Expert Opin Drug Saf. 2012. PMID: 22913713
-
Extrapyramidal adverse events associated with atypical antipsychotic treatment of bipolar disorder.
Gentile S. Gentile S. J Clin Psychopharmacol. 2007 Feb;27(1):35-45. doi: 10.1097/01.jcp.0000246217.34024.53. J Clin Psychopharmacol. 2007. PMID: 17224710 Review.
-
A meta-analysis of the efficacy of second-generation antipsychotics.
Davis JM, Chen N, Glick ID. Davis JM, et al. Arch Gen Psychiatry. 2003 Jun;60(6):553-64. doi: 10.1001/archpsyc.60.6.553. Arch Gen Psychiatry. 2003. PMID: 12796218
-
Nasrallah HA, Brecher M, Paulsson B. Nasrallah HA, et al. Bipolar Disord. 2006 Oct;8(5 Pt 1):467-74. doi: 10.1111/j.1399-5618.2006.00350.x. Bipolar Disord. 2006. PMID: 17042884
Cited by
-
Malla A, Ota A, Nagamizu K, Perry P, Weiller E, Baker RA. Malla A, et al. Int Clin Psychopharmacol. 2016 Nov;31(6):307-14. doi: 10.1097/YIC.0000000000000140. Int Clin Psychopharmacol. 2016. PMID: 27571460 Free PMC article. Clinical Trial.
-
Hermes E, Sernyak M, Rosenheck R. Hermes E, et al. Epidemiol Psychiatr Sci. 2014 Sep;23(3):281-8. doi: 10.1017/S2045796013000449. Epub 2013 Sep 5. Epidemiol Psychiatr Sci. 2014. PMID: 24007653 Free PMC article.
-
Relating Spontaneously Reported Extrapyramidal Adverse Events to Movement Disorder Rating Scales.
Widschwendter CG, Karayal ON, Kolluri S, Vanderburg D, Kemmler G, Fleischhacker WW. Widschwendter CG, et al. Int J Neuropsychopharmacol. 2015 Jun 26;18(12):pyv064. doi: 10.1093/ijnp/pyv064. Int J Neuropsychopharmacol. 2015. PMID: 26116494 Free PMC article. Clinical Trial.
-
Lack of tolerable treatment options for patients with schizophrenia.
Citrome L, Eramo A, Francois C, Duffy R, Legacy SN, Offord SJ, Krasa HB, Johnston SS, Guiraud-Diawara A, Kamat SA, Rohman P. Citrome L, et al. Neuropsychiatr Dis Treat. 2015 Dec 16;11:3095-104. doi: 10.2147/NDT.S91917. eCollection 2015. Neuropsychiatr Dis Treat. 2015. PMID: 26719694 Free PMC article.
-
Penders TM, Agarwal S, Rohaidy R. Penders TM, et al. Neuropsychiatr Dis Treat. 2013;9:463-5. doi: 10.2147/NDT.S43113. Epub 2013 Apr 4. Neuropsychiatr Dis Treat. 2013. PMID: 23589691 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources